Antivirals for Adult Patients Hospitalised with SARS-CoV-2 Infection: a Randomised, Phase II/III, Multicentre, Placebo-Controlled, Adaptive Study, with Multiple Arms and Stages. COALITION COVID-19 BRAZIL IX – REVOLUTIOn Trial Israel S. Maia , Aline Marcadenti , Viviane C. Veiga , Tamiris A. Miranda , Samara P. C. Gomes , Mariana B. S. Carollo , Karina L. Negrelli , Jackeline O. Gomes , Lucas Tramujas , Erlon O. Abreu-Silva , Glauco A. Westphal , Ruthy P. Fernandes , Jacques G. A. Horta , Deborah C. Oliveira , Uri A. P. Flato , Ricardo C. R. Paoliello , Camilo Fernandes , Cassio L. Zandonai , Juliana C. Coelho , Waldemar C. Barros , Juliana C. Lemos , Renata S. Bolan , Marcela M. Dutra , Otavio C. E. Gebara , Ana T. A. Lopes , Meton S. Alencar Filho , Jussara A. Arraes , Victor A. Hamamoto , Mauro E. Hernandes , Nicole A. Golin , Tiago M. Santos , Renato H. N. Santos , Lucas P. Damiani , Fernando G. Zampieri , Joao Gesto , Flavia R. Machado , Regis G. Rosa , Luciano C. P. Azevedo , Alvaro Avezum , Renato D. Lopes , Thiago M. L. Souza , Otavio Berwanger , Alexandre B. Cavalcanti LANCET REGIONAL HEALTH-AMERICAS（2023）
Key words
Antiviral, COVID-19, SARS-CoV2, Atazanavir, Daclatasvir, Sofosbuvir, Randomised controlled trial, Viral load, Acute respiratory failure, Hypoxemia
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
